![](https://endpts.com/wp-content/uploads/2020/09/Merdad-Parsey-Gilead-tile-scaled.jpg)
Merdad Parsey, Gilead CMO
Crown jewel in big Gilead buyout lands breakthrough designation for MDS
Months after Gilead snagged magrolimab in the $4.9 billion buyout of California biotech Forty Seven — the company’s largest acquisition in three years at the time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.